821Daclatasvir and Asunaprevir Plus Peginterferon Alfa-2a and Ribavirin in Patients With HCV Genotype 1 or 4 Infection: Phase 3 HALLMARK-QUAD Results
Bibliographic record
Abstract
Background. Daclatasvir (DCV) is a potent, pangenotypic NS5A inhibitor. Asunaprevir (ASV) is an NS3 protease inhibitor with activity in HCV genotypes (GT) 1 and 4. DCV plus ASV in combination with peginterferon alfa-2a and ribavirin (DCV + ASV + P/R) has previously demonstrated potent antiviral activity in HCV GT 1-infected null responders. This phase 3 study (HALLMARK-QUAD; AI447029) evaluated DCV + ASV + P/R in patients with chronic HCV GT 1 or 4 infection who were prior null or partial responders to peginterferon/ribavirin. Methods. In this open-label study, 354 GT 1 and 44 GT 4-infected patients received 24 weeks of treatment with DCV 60 mg once daily plus ASV 100 mg twice daily in combination with weekly peginterferon alfa-2a 180 µg and weight-based ribavirin twice daily. The primary endpoint was sustained virologic response at posttreatment Week 12 (SVR12). Results. The median age of patients was 53 years, 69% were male, 76% were white, and 23% had cirrhosis; 67% of patients were prior null responders and 33% were partial responders. SVR12 was achieved by 93% of GT 1-infected patients and 98% of GT 4-infected patients; one GT 4 patient was not tested for SVR12 but achieved SVR24, yielding an SVR rate of 100% in GT 4-infected patients (Table). Prior P/R response, cirrhosis status, gender, age, race, or IL28B genotype did not influence SVR12. SVR12 rates for GT 1a were 87% (153/176) vs 99% (176/178) for GT 1b. Serious adverse events occurred in 6% of patients; 5% discontinued treatment due to an adverse event. One death occurred at posttreatment week 12 (pneumonia; not considered related to study therapy). Adverse events occurring in ≥20% of patients were fatigue, headache, pruritus, asthenia, influenza-like illness, insomnia and rash. Grade 3/4 laboratory abnormalities included neutropenia (22%), lymphopenia (16%), anemia (6%), thrombocytopenia (4%) and ALT/AST elevations (3%/3%). Conclusion. The QUAD regimen of DCV + ASV + P/R demonstrated high SVR12 rates of 93% and 100% in GT 1 or GT 4 prior non-responders. DCV + ASV + P/R was generally well tolerated; no additional safety and tolerability concerns were observed compared to P/R regimens. These results support the investigation of DCV in all-oral combinations in multiple patient populations across genotypes. Disclosures. D. M. Jensen, AbbVie: Grant Investigator, Research grant and Research support; Boehringer Ingelheim: Grant Investigator, Research grant and Research support; BMS: Grant Investigator, Research grant and Research support; Roche/Genentech: Grant Investigator, Research grant and Research support; Pharmasset/Gilead: Grant Investigator, Research grant and Research support; Tibotec/Janssen: Grant Investigator, Research grant and Research support K. Sherman, Bristol-Myers Squibb: Investigator, Research grant S. Pol, Bristol-Myers Squibb: Board Member and Investigator, Research grant and Speaker honorarium S. Zeuzem, Bristol-Myers Squibb: Consultant, Consulting fee and Speaker honorarium V. De Ledinghen, AbbVie: Scientific Advisor, Consulting fee; BMS: Scientific Advisor, Consulting fee; Gilead: Scientific Advisor, Consulting fee; Merck: Scientific Advisor, Consulting fee; Janssen: Scientific Advisor, Consulting fee; Echosens: Scientific Advisor, Consulting fee A. Tran, Britsol-Myers Squibb: Investigator, Research grant and Research support M. Elkhashab, Bristol-Myers Squibb: Investigator, Research grant Z. H. Younes, Bristol-Myers Squibb: Investigator, Research grant S. Mauss, Britsol-Myers Squibb: Scientific Advisor, Speaker honorarium G. T. Everson, Bristol-Myers Squibb: Consultant and Investigator, Consulting fee, Research grant and Research support J. Vierling, Abbvie, Biotest, BMS, Gilead, Janssen, Vertex, Merck, Genentech, Genfit, Hyperion, Intercept, Ocera, Sundise: Research Contractor, Research support; Abbvie, Boerhinger-Ingelheim, BMS, Gilead, Janssen, Merck, Hyperion, Intercept, Sundise: Scientific Advisor, Consulting fee M. Brunetto, AbbVie, BMS, Gilead, Janssen, MSD, Roche, Novartis: Speaker's Bureau, Speaker honorarium D. Bernstein, Bristol-Myers Squibb: Investigator, Research grant F. Mcphee, BMS: Employee, Salary D. Hennicken, Bristol-Myers Squibb: Employee, Salary P. Mendez, Bristol-Myers Squibb: Employee, Salary E. Hughes, BMS: Employee, Salary S. Noviello, Bristol-Myers Squibb: Employee and Shareholder, Salary
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.001 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.003 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".